Marc C. Smaldone, MD, MSHP

Articles by Marc C. Smaldone, MD, MSHP

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Published: February 12th 2016 | Updated:

Marc C. Smaldone, MD, MSHP

Articles by Marc C. Smaldone, MD, MSHP

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

Low-Dose Cannabinoids Show Potential to Restore Serotonin Levels and Reduce Inflammation in HIV, Study Finds

FDA Approves New Dosing Strength of Xolair Biosimilar, Omlyclo

FDA Accepts Furosemide Autoinjector sNDA for Treatment of Edema in Chronic Kidney Disease or Chronic Heart Failure

Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients

Longevity Medicine: Just Another Reincarnation of Diet and Exercise or Something Altogether Different?